These insights also identify PIEZO1 as a potential therapeutic target for modulating dysregulated IFN responses in the contexts of autoimmune diseases and autoreactive inflammation wherein a crucial role of pDC-derived type I IFNs is established [12]. The gene discussed is PIEZO1; the disease is autoimmune disease.